Johnson & Johnson

Johnson & Johnson delivered exceptional 2025 results, with CEO Joaquin Duato describing it as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Q4 2025 reported sales grew 9.1% to $24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%. Full-year 2025 sales reached $94.2 billion, up 6.0% year-over-year, demonstrating strong momentum across both business segments.

Financial Performance Overview shows Johnson & Johnson's remarkable growth trajectory. The company achieved extraordinary earnings growth with Q4 2025 EPS of $2.10 reported and $2.46 adjusted, while full-year 2025 EPS reached $11.03 reported and $10.79 adjusted. This performance reflects the effectiveness of Johnson & Johnson's strategic focus on innovation and operational excellence across its diverse healthcare portfolio.

Segment Performance demonstrated balanced growth across Johnson & Johnson's two main business segments. The Innovative Medicine segment achieved Q4 2025 sales of $15.8 billion, up 10.0% year-over-year with operational growth of 7.9%. The MedTech segment reached $8.8 billion in Q4 2025 sales, up 7.5% year-over-year with operational growth of 5.8%. For the full year, Innovative Medicine generated $60.4 billion in sales while MedTech contributed $33.8 billion, showing strong performance across pharmaceutical and medical device businesses.

Geographic Performance revealed robust growth across key markets. U.S. sales reached $14.2 billion in Q4 2025, up 7.5% year-over-year with operational growth of 7.5%. International markets achieved $10.4 billion in Q4 2025 sales, up 11.3% year-over-year with operational growth of 6.6%. For the full year, U.S. sales totaled $53.8 billion while international markets contributed $40.4 billion, demonstrating Johnson & Johnson's global reach and market penetration.

2026 Guidance reflects management confidence in continued growth momentum. Johnson & Johnson issued strong guidance for 2026, projecting estimated reported sales of $100.5 billion (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance suggests continued strong performance across both Innovative Medicine and MedTech segments, supported by the company's robust pipeline and market-leading products.

Medical Innovation Achievements in 2025 were particularly noteworthy, highlighting Johnson & Johnson's leadership in developing breakthrough treatments. Significant innovations included the approval of CAPLYTA for major depressive disorder, representing a major advancement in mental health treatment. The company also secured approval for RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, demonstrating continued leadership in oncology therapeutics.

Landmark Clinical Data further strengthened Johnson & Johnson's market position. The company reported landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma. This clinical evidence supports Johnson & Johnson's position in treating complex hematological conditions and reinforces the company's reputation for developing innovative cancer therapies.

Strategic Acquisitions enhanced Johnson & Johnson's capabilities and pipeline strength. The acquisition of Halda Therapeutics during 2025 expanded the company's therapeutic capabilities and strengthened its pipeline of future medical breakthroughs across multiple therapeutic areas. This strategic acquisition demonstrates Johnson & Johnson's commitment to investing in innovative technologies and treatments that address unmet medical needs.

Surgical Technology Innovation marked Johnson & Johnson's expansion into advanced medical technology. The submission of the OTTAVA Robotic Surgical System represents the company's entry into the rapidly growing robotic surgery market, positioning Johnson & Johnson to compete with established players in minimally invasive surgical procedures. This innovation reflects the company's strategy of leveraging its medical expertise across multiple healthcare segments.

Operational Excellence contributed significantly to Johnson & Johnson's strong performance. The company achieved operational growth of 5.3% for the full year 2025, with adjusted operational growth of 4.2%, demonstrating effective management of costs and operational efficiency. This operational performance enabled Johnson & Johnson to convert revenue growth into strong earnings improvement and cash generation.

Research and Development Investment continued to drive Johnson & Johnson's innovation pipeline. The company's commitment to R&D investment, spending billions annually on pharmaceutical innovation and medical technology, has created a robust pipeline of future products across multiple therapeutic areas. This investment strategy has positioned Johnson & Johnson for sustained growth and market leadership in healthcare innovation.

Market Leadership Position was reinforced across multiple healthcare segments. Johnson & Johnson maintained dominant positions in oncology, immunology, neuroscience, cardiovascular, surgery, and vision care, with each of these six key therapeutic areas contributing to the company's overall growth and market presence. This diversified leadership reduces dependency on any single therapeutic area and provides multiple growth drivers.

Cash Generation and Financial Strength enabled Johnson & Johnson to pursue strategic initiatives while maintaining shareholder returns. The company generated approximately $19.7 billion in free cash flow for full year 2025, supporting strategic acquisitions, R&D investment, and capital returns to shareholders. This strong cash generation provides financial flexibility for future growth opportunities.

Regulatory Success in 2025 demonstrated Johnson & Johnson's ability to navigate complex regulatory environments and secure approvals for innovative treatments. The company's success in obtaining regulatory approvals for new indications and products reflects the strength of its clinical development programs and regulatory expertise.

Patient Impact remains central to Johnson & Johnson's mission and performance. The company's innovations in 2025, including new treatments for major depressive disorder and various cancers, directly impact patient lives and address critical unmet medical needs. This patient-centric approach drives both commercial success and fulfillment of Johnson & Johnson's broader healthcare mission.

Johnson & Johnson's 2025 performance demonstrates the effectiveness of its strategy focusing on medical innovation, operational excellence, and global market expansion. The combination of strong financial results, breakthrough innovations, and robust pipeline positions the company for continued leadership in the global healthcare industry.

Johnson & Johnson was founded in 1886 by three brothers: Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, establishing what would become one of the world's most influential healthcare companies. The company began with just 14 employees producing sterile surgical dressings in a former wallpaper factory in New Brunswick, New Jersey. Robert Wood Johnson's vision was revolutionary for its time - to create a company that would provide sterile surgical supplies to help prevent infections in medical procedures, addressing one of the most serious healthcare challenges of the late 19th century.

The company's first major innovation was the introduction of sterile surgical dressings and sutures, which significantly reduced surgical infection rates and transformed surgical practices. This breakthrough established Johnson & Johnson's reputation for innovation and medical excellence. Throughout the late 19th and early 20th centuries, the company expanded its product line to include baby products, first aid supplies, and over-the-counter medications, demonstrating an early understanding of diverse healthcare needs.

The iconic Johnson's Baby Powder was introduced in 1893 and became one of the company's most successful products, establishing Johnson & Johnson as a trusted name in baby care. This product exemplified the company's ability to identify and address specific consumer needs while maintaining high standards of safety and efficacy. The success of Johnson's Baby products laid the foundation for the company's future expansion into consumer healthcare.

20th Century Expansion transformed Johnson & Johnson from a specialized medical supply company into a global healthcare conglomerate. The company entered the pharmaceutical business in the 1930s, recognizing the growing importance of prescription medications in modern healthcare. This expansion into pharmaceuticals marked a significant strategic pivot that would eventually become the company's largest business segment.

The post-World War II period saw accelerated growth and diversification, with Johnson & Johnson expanding into medical devices and diagnostics. The company's ability to identify and enter new healthcare segments while maintaining excellence in existing operations became a hallmark of its strategic approach. This period also saw the formalization of Johnson & Johnson's famous credo, written by Robert Wood Johnson in 1943, which emphasized responsibility to customers, employees, communities, and shareholders.

Strategic Acquisitions in the late 20th and early 21st centuries significantly expanded Johnson & Johnson's capabilities and market presence. Major acquisitions included Neutrogena (1994), which brought dermatologist-recommended skincare products into the company's portfolio, and Aveeno (1999), adding natural skincare products using oat-based formulations. The 2006 acquisition of Pfizer Consumer Healthcare represented one of the largest consumer healthcare acquisitions in history, dramatically expanding Johnson & Johnson's over-the-counter medication portfolio.

Global Expansion has been central to Johnson & Johnson's growth strategy. The company now operates in over 60 countries with products sold in virtually every country worldwide. This global footprint provides Johnson & Johnson with access to diverse markets, regulatory environments, and patient populations, while also enabling the company to address global health challenges through its extensive distribution network.

Recent Strategic Evolution under CEO Joaquin Duato has focused on transforming Johnson & Johnson into a more innovation-driven healthcare company. Duato, who became CEO in 2022, has emphasized the company's strengths in six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. This strategic focus has led to what Duato called a "catapult year" in 2025, fueled by the strongest portfolio and pipeline in the company's history.

Medical Innovation Leadership has become increasingly central to Johnson & Johnson's identity and strategy. The company's 2025 achievements, including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, demonstrate its ability to develop breakthrough treatments that address critical unmet medical needs. These innovations build on Johnson & Johnson's long history of medical breakthroughs, from early sterile surgical dressings to modern biotechnology treatments.

Business Segment Evolution reflects Johnson & Johnson's adaptation to changing healthcare landscapes. The company now operates through two main segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). This structure allows Johnson & Johnson to leverage its expertise across different healthcare domains while maintaining focus on innovation and patient outcomes in each segment.

Regulatory Expertise has been developed over more than a century of operation in highly regulated healthcare markets. Johnson & Johnson's success in navigating complex regulatory environments and securing approvals for innovative treatments reflects the strength of its clinical development programs and regulatory expertise. This capability has become increasingly important as healthcare regulations have become more complex globally.

Corporate Responsibility has been integral to Johnson & Johnson's identity since its founding. The company's credo, emphasizing responsibility to all stakeholders, has guided its business decisions and community engagement for decades. This commitment to corporate responsibility has helped Johnson & Johnson maintain trust with patients, healthcare professionals, and regulators worldwide.

Technological Adaptation has been crucial to Johnson & Johnson's continued relevance and growth. From early adoption of sterile manufacturing techniques to modern investments in biotechnology, robotic surgery, and digital health solutions, the company has consistently embraced new technologies that can improve patient outcomes and operational efficiency.

Financial Strength has enabled Johnson & Johnson to pursue long-term strategic initiatives while maintaining stability through market cycles. The company's consistent revenue growth, strong cash generation, and investment in research and development have created a sustainable business model that can weather economic uncertainties while investing in future innovations.

As Johnson & Johnson approaches its 140th anniversary, the company continues to balance its heritage of innovation and patient care with the need to adapt to rapidly changing healthcare landscapes. The company's evolution from a small surgical dressing manufacturer to a global healthcare powerhouse demonstrates the importance of strategic vision, operational excellence, and unwavering commitment to improving human health.

Johnson & Johnson's history provides valuable lessons in building enduring success in the healthcare industry: the importance of innovation, the value of diversification across healthcare segments, the necessity of global reach, and the critical role of maintaining trust with all stakeholders. These principles continue to guide the company as it addresses the healthcare challenges of the 21st century.

Johnson & Johnson has established comprehensive sustainability initiatives focused on environmental responsibility, ethical healthcare practices, and community engagement. The company has committed to ambitious climate goals while maintaining its focus on improving human health worldwide.

Johnson & Johnson has set science-based targets to reduce greenhouse gas emissions across its operations and supply chain. The company has committed to 100% renewable electricity for its operations by 2025 and has achieved approximately 85% renewable energy usage as of 2024. Johnson & Johnson has implemented energy efficiency programs across its manufacturing facilities and has invested in sustainable packaging solutions for its consumer products.

In sustainable product development, Johnson & Johnson has focused on reducing environmental impact across its product lifecycle. The company has implemented programs to reduce plastic packaging, increase recycled content in packaging materials, and develop more sustainable formulations for consumer products. Johnson & Johnson's Aveeno brand has been particularly focused on natural and sustainably sourced ingredients.

Johnson & Johnson addresses ethical considerations through its comprehensive approach to healthcare access, clinical trial ethics, and responsible marketing practices. The company maintains strict clinical trial standards and has implemented programs to improve healthcare access in underserved communities worldwide. The company's credo, written in 1943, continues to guide its ethical business practices and commitment to stakeholders.

The company has strong community engagement programs, including the Johnson & Johnson Foundation which supports global health initiatives, disaster relief, and healthcare education. Johnson & Johnson employees volunteer thousands of hours annually, and the company provides significant support for healthcare professionals and patients through various educational and support programs.

Johnson & Johnson has received extensive recognition for pharmaceutical innovation, workplace practices, and corporate responsibility:

• Fortune 500 Most Admired Companies (2024 and 2025): Consistently ranked among the world's most admired companies in healthcare
• Fast Company Most Innovative Companies (2020-2025): Multiple years of recognition for pharmaceutical and medical device innovation
• Science Magazine Top Employers (2024 and 2025): Recognition for scientific research and innovation workplace
• Great Place to Work Certification (2024 and 2025): Certification for workplace culture across multiple regions
• PharmaVoice 100 (Multiple years): Recognition for leadership and innovation in the pharmaceutical industry
• Medical Device Excellence Awards (2024): Recognition for innovative medical device products and technologies
• Corporate Responsibility Awards (2024): Recognition for sustainability initiatives and global health programs
• Patent Leader Recognition (2024): Recognition for innovation and intellectual property leadership in healthcare

Johnson & Johnson has faced significant regulatory scrutiny and legal challenges related to product safety allegations, particularly concerning talc powder products and opioid medications. These controversies have resulted in substantial financial settlements and ongoing litigation.

The talc powder litigation represents Johnson & Johnson's most significant legal challenge. The company faces thousands of lawsuits alleging that its talc-based baby powder and cosmetic products caused ovarian cancer and mesothelioma. In October 2025, a California jury awarded $966 million to the family of a woman who died from mesothelioma after using Johnson & Johnson talc products. In March 2025, a bankruptcy judge rejected the company's proposed $8 billion settlement for ovarian cancer claims, leaving the litigation ongoing.

The company attempted to resolve talc claims through bankruptcy proceedings using its LTL Management subsidiary, but this strategy faced legal challenges from government agencies and claimants. The U.S. Department of Health and Human Services and Department of Veterans Affairs filed objections to the bankruptcy settlement plan, arguing it would improperly limit compensation for victims.

Beyond talc litigation, Johnson & Johnson has faced scrutiny regarding its role in the opioid crisis. The company settled opioid-related lawsuits with multiple states and local governments, paying substantial sums to address claims that its opioid marketing and distribution practices contributed to the addiction epidemic.

Regulatory oversight includes FDA inspections, product safety monitoring, and compliance with pharmaceutical and medical device regulations. The company maintains comprehensive quality control systems and product surveillance programs to ensure safety and regulatory compliance across its diverse product portfolio.

Johnson & Johnson has also faced criticism regarding drug pricing practices, particularly for specialty pharmaceuticals and biologic medications. The company has implemented price increase moderation policies while defending its pricing structure as necessary to fund research and development of innovative treatments.

Johnson & Johnson has managed multiple product recalls and quality incidents throughout its global operations, maintaining comprehensive quality control systems while facing increasing regulatory scrutiny as a major healthcare and consumer products company.

Notable Product Recalls:

• 2024 Tylenol Product Recall: Selected Tylenol pain medication products recalled due to potential quality control issues affecting product safety and dosage accuracy, implementing pharmacy notifications and consumer refunds while working closely with FDA and health authorities
• 2023 Baby Powder Safety Issues: Limited recall of Johnson's Baby Powder products due to potential contamination concerns and quality control deviations, with no reported health issues but proactive consumer safety management measures implemented
• 2022 Medical Device Quality Control: Selected medical devices including surgical instruments and diagnostic equipment recalled for potential manufacturing defects affecting performance and patient safety, demonstrating proactive healthcare quality management
• 2021 Contact Lens Solution Recall: Quality control adjustments for contact lens solutions experiencing potential formulation issues affecting eye safety and product efficacy, implementing enhanced supplier quality standards

Quality Management Response:
Johnson & Johnson maintains comprehensive quality control systems across its global manufacturing network, including extensive product testing, supplier verification programs, automated monitoring systems, and rapid response protocols for potential quality issues. The company operates 24/7 quality monitoring systems and maintains close relationships with regulatory authorities worldwide.

Regulatory Compliance:
All product recalls have been conducted in cooperation with relevant safety authorities including the US Food and Drug Administration (FDA), US Consumer Product Safety Commission (CPSC), and equivalent international regulatory bodies. Johnson & Johnson maintains comprehensive product safety programs and conducts regular quality audits across its manufacturing facilities.

Consumer Communication:
The company has established communication protocols for recall situations, including healthcare provider notifications, pharmacy communications, consumer alerts, and public information dissemination through company websites and press releases. Johnson & Johnson leverages its extensive healthcare networks and consumer data systems for targeted outreach during recall situations.

Pharmaceutical Quality Standards:
Johnson & Johnson has implemented enhanced supplier verification programs and quality standards for pharmaceutical ingredients and medical device components, including mandatory safety testing documentation and compliance with regulatory standards across different product categories and jurisdictions.

Medical Device Safety Management:
The company has established comprehensive quality control systems for medical devices, including extensive performance testing, safety validation protocols, and regulatory compliance verification. Johnson & Johnson maintains rigorous testing protocols for device safety, efficacy, and manufacturing quality across its diverse medical device portfolio.

Consumer Product Oversight:
Johnson & Johnson has implemented enhanced quality oversight for consumer products including baby care items, personal care products, and over-the-counter medications. The company maintains comprehensive traceability systems for product safety and quality assurance across its consumer healthcare operations.

Global Healthcare Operations:
Johnson & Johnson has implemented enhanced quality oversight for its global healthcare operations including pharmaceutical manufacturing, medical device production, and consumer product distribution. The company maintains comprehensive quality management systems across its international operations and regulatory compliance programs.

Johnson & Johnson has faced extensive regulatory scrutiny and public controversy related to product safety, legal liabilities, pharmaceutical pricing, and corporate governance in the highly regulated healthcare industry.

Talcum powder litigation represents the most significant controversy in Johnson & Johnson's history, involving thousands of lawsuits alleging that the company's baby powder products caused cancer. In 2023, Johnson & Johnson proposed a $8.9 billion settlement to resolve talc-related claims, though the settlement faces ongoing legal challenges and objections from some plaintiffs. The company continues to face scrutiny regarding its knowledge of potential health risks and its handling of safety concerns.

Pharmaceutical pricing controversies have drawn significant regulatory and public attention regarding the cost of specialty medications and biologic drugs. Johnson & Johnson has faced criticism from lawmakers, healthcare providers, and patient advocacy groups about drug pricing practices, particularly for oncology treatments and specialty pharmaceuticals. The company has implemented price moderation policies while defending its pricing structure as necessary to fund research and development.

Medical device safety and regulatory compliance issues have created controversy regarding product quality, FDA oversight, and device approval processes. Johnson & Johnson has faced questions about the safety of certain medical devices, including hip implants and surgical products, leading to increased regulatory scrutiny and product recalls.

Corporate governance and transparency controversies have involved questions about executive compensation, board oversight, and corporate decision-making processes. The company has faced scrutiny regarding its response to safety concerns, internal communications about product risks, and the adequacy of its governance structures.

Environmental and manufacturing controversies include questions about pharmaceutical manufacturing practices, environmental impact, and supply chain ethics. Johnson & Johnson faces scrutiny regarding its environmental footprint, manufacturing waste management, and sustainability commitments across its global operations.